Sol-Gel Technologies (SLGL) Set to Post Earnings on Thursday

Key Points

• Sol-Gel is expected to report Q3 2026 results before market open on November 19. Analysts forecast a loss of $2.07 per share and revenue of $0.15 million.
• In its prior quarter, the company reported a loss of $1.13 per share, better than the $2.36 loss analysts expected, and revenue of $0.59 million versus a $0.07 million estimate.
• Analyst sentiment is mostly positive: the stock has a consensus “Buy” rating and an average price target of $197.50, though one firm rates it a “Sell.”

Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 19th. Analysts expect the company to post earnings of ($2.07) per share and revenue of $0.15 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 16, 2026 at 12:30 PM ET.

Sol-Gel Technologies (NASDAQ:SLGL - Get Free Report) last issued its quarterly earnings results on Friday, August 21st. The company reported ($1.13) EPS for the quarter, topping the consensus estimate of ($2.36) by $1.23. The firm had revenue of $0.59 million during the quarter, compared to analyst estimates of $0.07 million. Sol-Gel Technologies had a negative net margin of 910.14% and a negative return on equity of 44.05%. On average, analysts expect Sol-Gel Technologies to post ($5.37) EPS for the current fiscal year and ($5.64) EPS for the next fiscal year.

Sol-Gel Technologies Stock Up 3.1%

NASDAQ:SLGL opened at $63.40 on Thursday. The company has a market cap of $207.32 million, a P/E ratio of -11.24 and a beta of 1.25. The firm's 50 day moving average is $67.23 and its two-hundred day moving average is $73.85. Sol-Gel Technologies has a fifty-two week low of $28.81 and a fifty-two week high of $97.97.

Insider Transactions at Sol-Gel Technologies

In other Sol-Gel Technologies news, major shareholder Opaleye Management Inc. purchased 1,493 shares of the business's stock in a transaction that occurred on Friday, September 11th. The shares were purchased at an average price of $65.94 per share, for a total transaction of $98,448.42. Following the completion of the acquisition, the insider owned 540,000 shares of the company's stock, valued at approximately $35,607,600. This represents a 0.28% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have purchased 53,430 shares of company stock worth $3,684,739. 66.51% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on SLGL. Weiss Ratings restated a "sell (d-)" rating on shares of Sol-Gel Technologies in a report on Tuesday, September 1st. HC Wainwright reiterated a "buy" rating and issued a $110.00 target price on shares of Sol-Gel Technologies in a report on Monday, October 19th. Cantor Fitzgerald began coverage on Sol-Gel Technologies in a report on Wednesday, October 14th. They issued an "overweight" rating on the stock. Finally, Zacks Research raised Sol-Gel Technologies from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 15th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $197.50.

About Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a dermatology-focused specialty pharmaceutical company based in Israel. The company develops and commercializes topical prescription medicines for common skin conditions, using proprietary delivery technologies designed to improve the stability, tolerability, and effectiveness of active pharmaceutical ingredients. Its marketed products include Epsolay, a topical benzoyl peroxide cream indicated for the treatment of inflammatory lesions associated with rosacea, and Twyneo, a fixed-dose topical combination of tretinoin and benzoyl peroxide for acne vulgaris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.